ACOTEC
先瑞达

Acotec Scientific Holdings Limited

2026H1 Business Performance Review

Sep. 2026

TRUSTED INNOVATION
FOR LIFE

ACOTEC
先瑞达

Legal Disclaimer

- This Presentation is strictly confidential and subject to the terms and conditions described below. It is only sent to some people and provided with information about Acotec Scientific Holdings Limited (the "Company") to help you decide whether to conduct in-depth research on the Company. The information contained in this Presentation has not been verified by any regulatory agency in any jurisdiction. The content of this Presentation (regardless of all or part of the content and regardless of the purpose) shall not be copied, distributed or shared directly or indirectly with any person (regardless of whether such person is a member of your company or group). In particular, neither the information contained in this Presentation nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in the United States, Canada, Australia, Japan, Hong Kong, Singapore or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of U.S. or other national securities laws. Anyone who obtains this Presentation should understand or be familiar with such restrictions.
- This Presentation and the information contained therein have not been independently verified and are not intended to constitute the basis for making investment decisions. The content of this Presentation does not constitute or form and shall not be construed as a solicitation of an offer for the sale or purchase of securities under any other jurisdiction. Any part of this Presentation does not constitute the basis of any contract or undertaking. Any decision to purchase the Company's securities in a public or private offering shall be based on the prospectus or international offering circular prepared by the Company for the relevant securities offering and any supplementary price information. This Presentation does not include any information or materials that would cause this Presentation to constitute(i) a prospectus under Section 2(1) of the Companies (Winding Up and Miscellaneous Provisions) (Cap.32 of Hong Kong) or the Securities Act of 1933 (as amended) (the “Securities Act"), or an advertisement in relation to a prospectus or proposed prospectus, or an extract from or abridged version of a prospectus under Section 38B of the Companies (Winding-up and Miscellaneous Provisions), or an advertisement, invitation or document which contains any advertisement or invitation under Section 103 of the Securities and Futures Ordinance (Cap. 571 of Hong Kong), or (ii) an invitation to the public made in Hong Kong without abiding by Hong Kong law or introducing exemptions under Hong Kong law. This Presentation is subject to change without notice.
- The Company’s securities have not been and will not be registered under the Securities Act or the securities law of any state in the United States, and may not be offered or sold in the United States without registration or obtaining relevant applicable exemptions. Neither this Presentation nor its content constitutes or forms, and shall not be construed as part of an offer or solicitation of an offer to subscribe for securities in the United States. The Presentation shall not be carried or transmitted to the United States (including its territories and commonwealths, any state or the District of Columbia), or distributed directly or indirectly in the United States (including its territories and commonwealths, any state or District of Columbia). The Company's securities will not be offered or sold in the United States except for transactions that are not subject to exemptions under the provisions of the Securities Act or not subject to the Securities Act.
- By participating in or by reading this Presentation, you are recognized to have made representations and warranties to the Company, the parties involved in the Company’s securities issuance, or their respective affiliates, controllers, directors, managers, partners, employees, agents, representatives or advisors that you and any you represent (if any) are either (i) a “qualified institutional buyer” (within the meaning of Rule 144A under the United States Securities Act of 1933, as amended), or (ii) outside the United States.. You are also deemed to have represented and agreed that you and any customers you represent are professional investors as defined in the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and any rules made thereunder.
- The information in this Presentation is provided by the Company. This Presentation is not intended to be comprehensive or to contain all the information you may need to evaluate the Company. Regarding the accuracy, reliability, correctness, reasonableness, fairness or completeness of this Presentation or any information therein, or any oral or written communication regarding the evaluation of the Company, none of the parties (to avoid ambiguity, including but not limited to the Company, the parties involved in the Company’s securities issuance, or their respective affiliates, controllers, directors, managers, partners, employees, agents, representatives or advisors) has or will make any express or implied statement or guarantee, and shall not, within the scope permitted by law, assume any liability arising therefrom. In particular, regarding the realization or reasonableness of any assumptions, speculations, goals, estimates or prospects contained in this Presentation, no express or implied statements or guarantees are made, nor should you rely thereon. Some of the information contained herein comes from different sources, including some third parties, and has not been independently verified by the Company. For the losses caused to you or any person using or relying on the information contained or disclosed in this Presentation, the Company, the parties involved in the Company’s securities issuance, or their respective affiliates, controllers, directors, managers, partners, employees, agents or representatives shall take no responsibility (whether in negligence or otherwise). The use of registered trademarks, commercial trademarks and logos or photographic materials within this Presentation are exclusively for illustrative purposes and are not meant to violate the rights of the creators and/or applicable intellectual property laws.
- This Presentation is subject to the disclaimer and restrictive language contained therein. Any person shall make their independent evaluation and analysis, and shall not use any information mentioned, discussed or quoted in therein as the basis for their actions. You understand and assure the Company, the parties involved in the Company’s securities issuance, or their respective affiliates, controllers, directors, managers, partners, employees, agents, representatives or advisors that you are a professional investor and have the knowledge, experience and ability required to evaluate the Company, you will make independent evaluation of the Company, its securities and all the information provided, and you have or will obtain independent advice for the evaluation of the Company’s securities.
- This Presentation may contain the Company’s current beliefs and expectations regarding the indicated future dates. Such forward-looking statements are based on some assumptions about the Company’s operations or factors outside the Company’s control, and may be affected by a number of known and unknown factors. Therefore, the Company’s actual performance may be materially different from these forward-looking statements. You shall not rely on such forward-looking statements. The Company, the parties involved in the issuance of the Company’s securities, or their respective affiliates, controllers, directors, managers, partners, employees, agents, representatives or advisors shall not be obliged to update or revise such forward-looking statements in response to new information, events or circumstances that occur after these dates.
- This Presentation and the information contained therein are strictly confidential. This Presentation and the information contained therein shall not be copied, reproduced, or transmitted to others in any form, or disclosed for any purpose (whether in whole or in part). Failure to comply with these restrictions may constitute a violation of the law and may result in legal or regulatory action. By receiving this Presentation or the information therein, you agree (1) that you have read and agree to abide by the requirements in this disclaimer; and (2) that you will keep the information contained in this Presentation strictly confidential.
- By participating in and accepting this Presentation, you agree to maintain the absolute confidentiality of the information contained in this Presentation and accept the restrictions and other conditions stated therein. Failure to comply with these restrictions and conditions may violate relevant laws and regulations and result in legal or regulatory measures.

ACOTEC
先瑞达

01 2026H1 Financial Performance Review

02 The Progress on BSC Collaboration

03 Product Commercialisation

04 R&D, Regulatory Approvals & Manufacturing

05 Q&A

TRUSTED INNOVATION
FOR LIFE

TRUSTED INNOVATION
FOR LIFE

01

2026H1 Financial Performance Review

2026H1 Financial Performance Review (1/3)

TRUSTED INNOVATION
FOR LIFE

Revenue

(In millions RMB)



- **Revenue was RMB 332mn in 2026H1**, down 5.6% yoy, due to the implementation of the national volume-based procurement (VBP) for peripheral and coronary DCBs, under which we reduced DCB selling prices and provided one-off compensation to distributors for channel inventory.
- **Overseas revenue reached RMB 35.6mn, up 223% yoy**, lifting its share of total revenue from 3% in 2025H1 to 11% in 2026H1, driven by the sales ramp-up of the RFA system in the U.S. and steady global DCB sales.
- **Revenue from venous intervention, vascular access and other products was RMB 191mn, up 36% yoy**, accounting for 57.5% of total revenue and emerging as a key growth driver for the Company.

Gross Profit & Gross Margin

(In millions RMB)



- **Gross profit was RMB 233mn, with gross margin at 70.3%,** down slightly yoy due to DCB price reductions following VBP implementation. The Company's ongoing cost initiatives—including self-produced raw materials, process optimisation, and automation—have improved margins for venous products and others, partially offsetting the overall decline.

2026H1 Financial Performance Review (2/3)

TRUSTED INNOVATION
FOR LIFE

R&D expenses



- R&D expenses were RMB 239mn in 2026H1, including a one-off non-cash impairment loss and a one-off provision related to the discontinuation of the U.S. clinical program for the BTK DCB, totalling approximately RMB151 mn. Excluding this item, **the R&D expense ratio was 27%, continuing to improve yoy.**

Selling and distribution expenses



- **Selling expenses were approximately RMB 40.8mn, down 26.8% yoy**, with the **selling expense ratio** declining from 16% in 2025H1 to **12%.** The decrease primarily reflected lower market-related expenditures following VBP implementation, more disciplined event planning and more granular operational management.

Administrative expenses



- Administrative expenses were approximately **RMB 32.5mn**, representing 9.8% of revenue and remaining within an **efficient and stable range.**

2026H1 Financial Performance Review (3/3)

Net Profit & Adjusted Net Profit

(In millions RMB)



- Net loss for 2026H1 was RMB 80.8mn, primarily attributable to a one-time non-cash impairment loss and provisions totalling approximately RMB 151mn related to the termination of the BTK DCB U.S. clinical trial.
- Excluding the one-off impact of the program discontinuation and further adjusting for share-based payments of approximately RMB 3.5mn and foreign exchange losses of approximately RMB 17mn, the Company achieved **an adjusted net profit of approximately RMB 90.6mn**. The underlying business remained resilient, and the Company's core earnings capacity was intact.

Liquidity and Financial Resources

- As of June 30, 2026, the Company's available financial resources totaled approximately **RMB 850 million**.
- These ample cash reserves ensure stable operations and support business development opportunities.

02

The Progress on BSC Collaboration

Synergy for Success: From Foundation to Revenue Acceleration

H1 2026 | BSC Collaboration Overseas Revenue

RMB ~35mn

+200% YoY

H1 2025: RMB ~11mn

Revenue growth is accelerating

Phase 2 is focused on scaling commercial success.

Phase 1

2023-2025

Foundation & Capability Building

Phase 2

2026-2028

Acceleration & Momentum Scaling

Key Capabilities Strengthened in Phase 1

Product Registration & Compliance

- Expanded in-house regulatory team to accelerate overseas market entry.

Quality Management

- Enhanced our existing QMS to meet and maintain compliance with evolving overseas regulatory requirements.

Manufacturing Capacity

- Upgraded production facilities and expanded manufacturing capacity to support volume scale-up.

Supply Chain & Logistics

- Established a responsive supply chain to ensure reliable delivery and rapid responsiveness to customer needs.

Key Updates on Collaboration with BSC: Product Commercialisation

TRUSTED INNOVATION
FOR LIFE

Cedar
Endovenous Radiofrequency Ablation System

Core revenue growth driver from BSC collaboration

√ MARKET ACCESS	√ COMMERCIALISATION	√ EARLY ADOPTION
FDA 510(k) clearance Oct 2025	U.S. commercial launch by BSC	Positive clinical feedback received

DCB Global Collaboration


SFA DCB
AcoArt Orchid®


BTK DCB
AcoArt Tulip® & Litos®

20+ Countries where products have been launched outside of China

3 new regulatory approvals in H1 2026
Overseas expansion continues...

Coronary Portfolio

The scope of collaboration covers a broad product set


Coronary DCB Camellia®


Coronary DCB Canna®


PTCA Balloon YAN

.....

3 Co-developed peripheral intervention products

Jointly developing products with BSC for North America and Asia-Pacific markets.

First commercialisation expected in 2027

* Global distribution shown for illustrative purposes only.

Key Updates on Collaboration with BSC: R&D and Manufacturing Services

TRUSTED INNOVATION
FOR LIFE

JOINT R&D

3

projects in development

North America & Asia-Pacific

Concept & Design Input	Product Development	Regulatory Approval	Commercialization
BOTH	ACOTEC	ACOTEC	BSC

Milestone-based payments from BSC for R&D services.

2027
First co-developed product expected to be commercialized

OEM

Manufacturing Services

Neuromodulation Product

Supply agreement signed in 2025

- OEM manufacturing of a BSC neuromodulation product.
- First prototypes rolled off the production line in 2025.

Manufacturing capability validated.

GX1

Prototype milestone

AGOTEC
先瑞达

TRUSTED INNOVATION
FOR LIFE

03

Product Commercialisation

Commercialisation enters a multi-engine phase: Established franchises underpin the core business, while new products and overseas expansion drive incremental growth.

TRUSTED INNOVATION
FOR LIFE

Venous Intervention, Vascular Access and Others

+36% YoY

Continued rapid growth in 2026H1

Overseas Revenue

+223% YoY

Steady progress in overseas commercialisation

Anchor Franchise

SFA DCB

BTK DCB

Peripheral DCBs

- Poised for volume growth in the post-VBP era.
- Long-term clinical evidence and case accumulation have built a solid foundation of trust.

Core Growth Engine

Peripheral Aspiration System

RFA System

Peripheral Venous Products

- Rapidly increasing therapy penetration.
- First-mover advantage and market leadership support continued growth in clinical utilization.

New Growth Driver

Vertebral Artery DCB

Peripheral Coil

High-Potential Products

- Newly launched products such as the vertebral artery DCB and peripheral coils, together with upcoming pipeline approvals, are expected to diversify revenue growth.

Accelerator

Peripheral DCBs

RFA System

Overseas products

- With the gradual expansion of the Boston Scientific collaboration—both in products and countries covered—overseas market revenue is expected to become an increasingly important growth contributor.

DCB: Robust Clinical Evidence and Ongoing Physician Education Reinforce Market Leadership in the Post-VBP Era

TRUSTED INNOVATION
FOR LIFE

China's First SFA DCB

10+ Years of Commercial Use

AcoArt Orchid® & Dhalia®

- China's first SFA DCB
- 5-year long-term follow-up data, 10 years of real-world clinical validation of safety and efficacy
- An established physician base and distribution network

First-mover advantage has translated into clinical trust and a sustainable commercial execution moat

China's First BTK DCB

5+ Years of Commercial Use

AcoArt Tulip® & Litos®

- China's first BTK DCB
- Robust evidence base from domestic and international clinical studies
- Deep physician education foundation

Solid clinical evidence and improving affordability support rapid volume growth.

The first Chinese-brand DCB for AVF

3+ Years of Commercial Use

AcoArt Avens®

- Strong unmet need for AVF maintenance; DCB therapy market is being rapidly cultivated
- VBP accelerates hospital coverage; low-base ramp-up with significant headroom

VBP accelerates product penetration and unlocks substantial market potential.

Ongoing Academic Engagement: Leveraging reliable clinical performance to drive clinical consensus building.

Venous Portfolio: Deepening Lower-Tier Market Penetration Through Therapy Adoption and Physician Training

TRUSTED INNOVATION
FOR LIFE

DVT / Peripheral Thrombosis

Peripheral Aspiration System AcoStream® Portfolio

Complete Solution× Broad Hospital Coverage× Continuous Product Iteration

Varicose Veins

Radiofrequency ablation system AcoArt Cedar®

Expand Hospital Coverage × Strengthen Physician Training × Deepen Channel Reach

Consolidating the advantage of a comprehensive aspiration solution

High-quality Clinical Evidence and End-to-End Physician Education

01 Deepen utilisation in existing centers

02 Expand hospital coverage and channel penetration

03 Drive adoption through academic engagement and KOL advocacy

04 Differentiate through a comprehensive product portfolio

Complete Product Matrix × First-Mover Advantage× Broad Channel Coverage

New Product Commercialisation: From Approval to Hospital Access, Lighthouse Cases and Physician Education (1/2)



NMPA approved in 2025

First of Its Kind in China

AcoArt Verbena®

Vertebral Artery Paclitaxel-Coated Balloon

13.04%

The restenosis rate at 12-month follow-up

vs. 37.31% (Stent Group)

50,000 VAOS interventions per year, growing at an average rate of 15%

- **Large patient pool**: VAOS is implicated in approximately 20% of posterior-circulation transient ischemic attacks and strokes, representing an estimated 150,000-200,000 additional potential patients each year.
- DCB therapy can address lesions in both dominant and non-dominant vertebral arteries

A "Leave nothing behind" interventional option for VAOS

Commercialisation Roadmap

01 Hospital Access
Rapidly establish product access

02 Reference Centres
Standardize procedural practice

03 Case Accumulation
Build real-world clinical evidence

04 Physician Education
Disseminate the treatment concept and technique

Pioneer: Building on Evidence, Leading the Evolution of Vertebral Artery Treatment Concepts

Concept Education × Technical Standardization × Reference Cases

Build awareness of "Leave nothing behind" therapy for VAOS through academic activities and education; accumulate reference cases at leading centers, then expand coverage to broader hospital networks.

New Product Commercialisation: From Approval to Hospital Access, Lighthouse Cases and Physician Education (2/2)

400,000+/year*

The usage volume of pushable coils and semi-detachable coils reached 400,000 units per year, while the penetration of controlled coils is increasing rapidly.

Hebei-led Inter-Provincial Alliance VBP Program

A notice for the follow-on VBP round has been issued.

Lavender | Peripheral Controlled Mechanically Detachable Fibered Coil

Complete detachment | Broad size range



2D Structure



3D Structure

01 Smooth delivery
More stable deployment

02 Precise control
Retrievable and repositionable before detachment

03 Complete mechanical detachment
Clear tactile feedback

04 High-density fibers
Greater embolization efficiency

05 Broad size range
Coverage across more clinical scenarios

VBP creates an opportunity to accelerate market access and volume ramp-up for this newly launched product.

Clinical evidence + Case demonstrations +Technical empowerment





Engagement with leading experts will build product awareness, while real-world cases will demonstrate handling and embolization performance.

* Based on market research.

VBP Expansion and Demand Recovery: Dual Drivers for Access Products' Volume Growth

TRUSTED INNOVATION
FOR LIFE

Peripheral Portfolio



Prepheral PTA Balloon AcoArt Iris® & Jasmin®

Prepheral PTA Balloon AcoArt Lily® & Rosmarin®

Prepheral Supporting Catheter Vericor®



Prepheral Tapered Balloon P-Conic®

Prepheral Scoring Balloon E-Peridge®

Prepheral High-pressure Balloon Armoni-HP®



Peripheral Hydrophilic Guidewire

Coronary Portfolio

Semi-compliant PTCA Balloon YAN

Coronary CTO Recanalization Balloon RT-Zero®

Coronary High-Pressure PTCA Balloon YIYAN

Coronary OTW Balloon Jingyi

Coronary CTO Antegrade Micro-Catheter Vericor-14®

Coronary CTO Retrograde Micro-Catheter Vericor-RS®



Coronary Micro-CatheterVericor-S2®

04

R&D, Regulatory Approvals & Manufacturing

We continuously expand R&D and production capabilities in core links of the industrial chain, focusing on building an innovation capability moat

TRUSTED INNOVATION
FOR LIFE

Raw Material Processing
Precision processing of polymers/metals

Core Component Development
Micro-extrusion molding / Balloon and catheter platform

Function Realization
Drug and functional coatings, Active energy control, Microsphere synthesis.....

Product Forming
System design / Performance verification

Large-scale Production
Process consistency / Quality and supply assurance

Precision Material Processing and Component Development

.....

Enables manufacturing of balloons, catheters, metal components, and microstructures

Establishing a robust process barrier from material to product realization

Drug/Functional Coating Technologies





.....

Determines drug loading, transfer efficiency, release and retention profile

Creating performance differentiation for products

Active Energy Control Technologies

.....

Capabilities in power control, temperature monitoring, impedance feedback, and consistent energy delivery

Building technological barriers for active medical devices

The Company has established a multi-dimensional technology platform that forms a complete value chain from raw material processing to large-scale production, driving R&D efficiency, product customization capability, and supply chain resilience.

Leveraging 30+ launched products, we offer a comprehensive multi-department treatment solution strategy, achieving a strong competitive edge through first-mover positioning and clinical recognition.

TRUSTED INNOVATION FOR LIFE

5 Core Covered Departments

32 Approved Products

30+ Countries with Overseas Approvals

Layout Strategy:

Focused on Vascular Surgery, expanding coverage and depth in key diseases. Vertically extending along "Access -> Preparation -> Treatment", and horizontally expanding across Cardiology, Neurology, Nephrology, and Oncology departments.

Vascular Surgery

Building a Complete Product Matrix Around Peripheral Arterial and Venous Diseases

Peripheral Arterial Atherosclerotic Stenosis

Access	Preparation	Treatment
• Support Catheter 1 • Microguidewire • New-gen Support Catheter	• PTA Balloon (SFA) • PTA Balloon (BTK) • Tapered PTA Balloon • Peripheral Scoring Balloon • Peripheral High-pressure Balloon	• SFA DCB 1 • BTK DCB 1 • Peripheral Sirolimus DCB .....

Arterial Aneurysm

- Peripheral Controlled Mechanically Detachable Fibered Coil
- .....

Venous Thromboembolism 1

- Aspiration System
- Intelligent Aspiration Sensing Connector
- Embolus Removal Device
- Delivery Catheter for Aspiration Catheter
- Introducer Sheath Set

Varicose Veins

- RFA System 1

Oncology

TACE

- TACE Microcatheter
- Embolization Microspheres

Cardiology

Forming a Complete Product Matix Around PCI, Focusing on CTO Lesions

PCI

Access	Preparation	Treatment
• Coronary CTO Antegrade Microcatheter • Coronary CTO Retrograde Microcatheter • Coronary Microcatheter	• Semi-compliant PTCA Balloon • Coronary CTO Recanalization Balloon • Coronary High-pressure Balloon • Coronary OTW Balloon • Coronary Knobby Balloon • Coronary IVL System	• Coronary Paclitaxel DCB • Coronary Sirolimus DCB

TAVR

- Cardiac Valve Balloon Dilation Catheter

Nephrology

AVF Stenosis

- Paclitaxel Coated High-pressure Balloon
- AV Scoring Balloon
- SFA DCB (AVF indication expansion)

Neurology

ICAS

- Intracranial PTA Balloon
- Intracranial DCB

VAO Stenosis

- Vertebral Artery DCB 1

Underdevelopment/registration/clinical trials

1 First launched in China/First domestic product approved in China

High-Potential Pipeline: Coronary IVL System and Intracranial DCB

TRUSTED INNOVATION
FOR LIFE



Coronary Calcified Lesions

Clinical Trial Ongoing
Approval expected in 2028

Coronary IVL System

- Uniform 360-degree energy delivery is designed to provide consistent and effective circumferential treatment.
- Enables reliable lesion expansion at high pressure with a favorable safety profile.
- Global patent filing strategy



Neurointervention

Registration Application Submitted
Approval Expected in 2027

Intracranial DCB

- Follow-up results have demonstrated strong clinical performance.
- Following launch, the product will broaden the Company's neurointervention portfolio and is expected to become a new growth driver.



* Images are for illustrative purposes only.

High-Potential Pipeline: Embolization Microspheres and Coronary Knobby Balloon

TRUSTED INNOVATION
FOR LIFE



Interventional Oncology

Registration Application Submitted
Approval Expected in 2027

Embolization Microspheres

- The product incorporates a new technology designed to improve drug-loading efficiency, shorten procedural preparation time and enhance embolisation performance.



Coronary Calcified Lesions

In Development
Approval Expected in 2027

Coronary Knobby Balloon

- The balloon's knobs and fiber-textured surface provide strong anchoring. Combined with non-compliant, high-pressure dilatation, the device is designed for calcified-lesion modification, post-dilatation following stent implantation and vessel preparation before DCB treatment.

* Images are for illustrative purposes only.

Dual - Base Synergistic Production Strategy: Sufficient Capacity for Growing Market Demand and OEM Business

TRUSTED INNOVATION
FOR LIFE

Advance supply-chain integration and strengthen manufacturing capabilities

Improve production and delivery efficiency to meet growing demand in the post-VBP era and support international expansion.

BEIJING	SHENZHEN
30,800㎡	11,543㎡




Lab/ Production Area / Office/ Clean Room

Dual Production Bases: Beijing & Shenzhen

Beijing New Facility

Shenzhen Manufacturing Facility

ACOTEC
先瑞达

TRUSTED INNOVATION
FOR LIFE

05

Q&A

AGOTEC
先瑞达

THANKS!

谢谢！

TRUSTED INNOVATION
FOR LIFE

Products and Pipeline-Full Product Portfolio (1/2)

TRUSTED INNOVATION
FOR LIFE

Department	Products and Product Candidates	Indications / Applications	Key Technologies	Phase				Upcoming Milestone
				Area	Pre-clinical Studies	Clinical Studies	Registration	
Vascular Surgery	AcoArt Orchid® & Dhalia®/Orchid Plus★ *Note 1*	Superficial femoral artery (SFA) and popliteal artery (PPA) disease	Drug coating technology	China	✓	✓	✓ NMPA Approval★	/
				EU	✓	✓	✓ CE★	/
	AcoArt Tulip®& Litos®★	Below-the-knee (BTK) artery disease	Drug coating technology	China	✓	✓	✓ NMPA Approval★	/
				EU	✓	✓	✓ CE★	/
	AcoArt Iris® & Jasmin®	PTA Balloon applied in PTA procedure	Polymer materials	China	✓	✓	✓ NMPA Approval★	/
	AcoArt Lily® & Rosmarin®	PTA Balloon applied in PTA procedure	Polymer materials	China	✓	✓	✓ NMPA Approval★	/
	Peripheral Aspiration System (AcoStream®)▲	DVT, ALI	Aspiration platform	China	✓	Exempted from clinical trial	✓ NMPA Approval★	/
	Radiofrequency Ablation System (AcoArt Cedar®)	Saphenous varicose veins	RF platform	China	✓	✓	✓ NMPA Approval★	/
	Peripheral Support Catheter (Vericor®)▲	Peripheral CTO lesion	Polymer materials	China	✓		✓ NMPA Approval★	/
				U.S.	✓		✓ FDA Approval★	/
				Brazil	✓	Exempted from clinical trial	✓ ANVISA Approval★	/
				Thailand	✓		✓ TFDA Approval★	/
				Japan	✓		✓ MHLW Approval★	/
	PTA Balloon (P-Conic®)	PTA	Polymer materials	China	✓	Exempted from clinical trial	✓ NMPA Approval★	/
	2nd Gen Peripheral Aspiration System (2nd Generation AcoStream®)▲	DVT, ALI	Aspiration platform	China	✓		✓ NMPA Approval★	/
				U.S.	✓	Exempted from clinical trial	○	2027
				EU	✓		○	2027
	Introducer Sheath Set (Acotrace)▲	PTA	Polymer materials	China	✓	Exempted from clinical trial	✓ NMPA Approval★	/
	Delivery Catheter for Aspiration Catheter▲	DVT	Polymer materials	China	✓	Exempted from clinical trial	✓ NMPA Approval★	/
	Pressure-Control Thrombus Aspiration Extension Tube▲	DVT	Aspiration platform	China	✓	Exempted from clinical trial	✓ BMPA Approval★	/
	Embolus Removal Device for Peripheral Thrombus Aspiration Catheter	DVT	Aspiration platform	China	✓	✓	✓ NMPA Approval★	/
	Peripheral Scoring Balloon (E-Peridge®)	PTA	Polymer materials	China	✓	✓	✓ NMPA Approval★	/
	Peripheral High-Pressure Balloon (Armoni-HP®)	CTO	Polymer materials	China	✓	✓	✓ NMPA Approval★	/
	Peripheral Hydrophilic Guidewire▲	PTA	Polymer materials	China	✓	Exempted from clinical trial	✓ BMPA Approval★	/
	Peripheral Controlled Mechanically Detachable Fibered Coil (Lavender)	Embolization	Polymer materials	China	✓	✓	✓ NMPA Approval★	/
	Lower Limb Sirolimus DCB	SFA and PPA disease	Drug coating technology	China	✓	✓	○	2027
	Next-Gen Peripheral Support Catheter▲	Peripheral CTO lesion	Polymer materials	China	✓	Exempted from clinical trial	○	2027

★Core product ☆ Indication expansion of core product ★Commercialisation

▲Exempted from clinical trial requirements in accordance with the Catalogue of Medical Device Exempted from Clinical Trials (《免於進行臨床試驗醫療器械目錄》) promulgated by the NMPA, as amended.

Note 1: We have been continuously improving the performance of AcoArt Orchid® & Dhalia®. As advised by NMPA and as part of our business strategy, we decided not to register Orchid Plus as a separate product. Alternatively, we applied to register Orchid Plus as an upgrade version of AcoArt Orchid® & Dhalia® with improved delivery balloon catheter system, and received the revised NMPA approval for AcoArt Orchid®& Dhalia® in November 2021.

Products and Pipeline-Full Product Portfolio (2/2)

TRUSTED INNOVATION
FOR LIFE

Department	Products and Product Candidates	Indications / Applications	Key Technologies	Phase				Upcoming Milestone
				Area	Pre-clinical Studies	Clinical Studies	Registration	
Cardiology	Semi-compliant PTCA Balloon (YAN) ▲	PTCA	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	/
	Coronary CTO Recanalization Balloon (RT-Zero®)▲	Coronary CTO	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	/
	Coronary CTO Antegrade Micro-Catheter (Vericor-14®) ▲	Coronary CTO	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	/
				Japan			MHLW Approval★	/
				Thailand			TFDA Approval★	/
	Coronary Retrograde Micro-Catheter (Vericor-RS®) ▲	Coronary CTO	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	
	Coronary High-Pressure Balloon (YIYAN) ▲	PTCA	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	
	Coronary Paclitaxel DCB (AcoArt Camellia®)	Coronary small vessel diseases	Drug coating technology	China			NMPA Approval★	
	Cardiac Valve Balloon (RunFlow®)	TAVR	Polymer materials	China			NMPA Approval★	
	Coronary Micro-Catheter (Vericor-S2®)▲	PCI	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	/
	Coronary Sirolimus DCB (AcoArt Canna®)	Bifurcation lesions	Drug coating technology	China			NMPA Approval★	/
	Coronary OTW Balloon Dilatation Catheter (Jingyi)	PTCA	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	/
	Coronary IVL System	Coronary lesion calcium	Polymer materials	China				2028
	Coronary Knobby Balloon Dilatation Catheter	PTCA	Polymer materials	China				2027
Nephrology	AcoArt Orchid®& Dhalia®/Orchid Plus☆(DCB)	Arteriovenous fistula stenosis	Drug coating technology	China			NMPA Approval★	/
	Paclitaxel Coated High-pressure Balloon (ACOART AVENS®)	AVF PTA procedure	Drug coating technology	China			NMPA Approval★	/
	AV Scoring Balloon (Peridge®)	AVF PTA procedure	Polymer materials	China			NMPA Approval★	/
Neurology	Intracranial PTA Balloon (NEO-Skater®)▲	Intracranial PTA procedure	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	/
	AcoArt Verbena® (DCB)	Vertebral atherosclerotic stenosis	Drug coating technology	China			NMPA Approval★	/
	Intracranial DCB (AcoArt Daisy®)	Intracranial atherosclerotic stenosis	Drug coating technology	China				2027
Oncology	Microcatheter (V-otter)	TACE	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	/
	Embolization Microspheres	TACE	Microsphere Synthesis Technology	China				2027

★Core product ☆ Indication expansion of core product ★Commercialisation

▲ Exempted from clinical trial requirements in accordance with the Catalogue of Medical Device Exempted from Clinical Trials (《免於進行臨床試驗醫療器械目錄》) promulgated by the NMPA, as amended.